Notice of Participation of the National Institute on Alcohol Abuse and Alcoholism (NIAAA) in PAR-19-146 "Drug Discovery For Nervous System Disorders (R21 Clinical Trials Not Allowed)"

Notice Number: NOT-AA-19-008

Key Dates
Release Date : February 01, 2019

Related Announcements
PAR-19-146

Issued by
National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Purpose

The purpose of this Notice is to inform potential applicants that the National Institute on Alcohol Abuse and Alcoholism (NIAAA) will participate, effective immediately, in the Funding Opportunity Announcement (FOA) PAR-19-146, " Drug Discovery For Nervous System Disorders (R21 Clinical Trials Not Allowed)".

The following sections of PAR-19-146 have been updated to reflect the participation of NIAAA in this Funding Opportunity Announcement.

Part 1. Overview Information

The following information has been added:

Components of Participating Organizations:

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Catalog of Federal Domestic Assistance (CFDA) Number(s):
93.273

Part 2. Section I. Funding Opportunity Description

Objectives:

The following information has been added:
NIAAA

NIAAA promotes discovery, synthesis and screening of novel small molecules for innovative priority targets, and supports evaluation of their efficacy in validated preclinical models to assess their therapeutic potential for treating alcohol dependence. The focus of proposed research projects should follow that described above and be relevant to the mission of NIAAA.

The identification and pursuit of agents towards novel targets previously un-recognized or understudied for the treatment of alcohol abuse disorders are especially encouraged. In particular, NIAAA encourages applications focusing on agents that alleviate craving and dysphoria during protracted abstinence, and agents effective in patients who have co-morbid psychiatric illnesses (e.g., schizophrenia, bipolar disorder).

Applications that essentially propose to further extend established or well-studied strategies and agents are not appropriate for this FOA.

Part 2. Section VII. Agency Contacts

The following contacts have been added:

Scientific/Research Contact(s):
Qi-Ying Liu, M.D.
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Telephone: 301-443-2678
Email: liuqiy@mail.nih.gov

Financial/Grants Management Contact(s):
Judy S. Fox
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Telephone: 301-443-4704
Email: jfox@mail.nih.gov

All other aspects of this FOA remain the same.

Inquiries

Please direct all inquiries to:

Qi-Ying Liu, M.D.
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Telephone: 301-443-2678
Email: liuqiy@mail.nih.gov